Declan Doogan

Dr. Declan Doogan is an Independent Director at Tenax Therapeutics, Inc., a Chairman at Causeway Therapeutics Ltd., a Director, Chief Scientific & Clinical Advisor at Celleron Therapeutics Ltd. and a Partner at Mediqventures Ltd. He is on the Board of Directors at BYOMass, Inc., Tenax Therapeutics, Inc., Juvenescence Therapeutics Ltd., Kleo Pharmaceuticals, Inc., Apterna Ltd., The Pulmonary Vascular Research Institute and Celleron Therapeutics Ltd. Dr. Doogan was previously employed as an Independent Director by Intensity Therapeutics, Inc., an Independent Chairman by Biohaven Pharmaceutical Holding Co. Ltd., an Independent Director by AlphaTON Capital Corp., a Chairman by Portage Pharma Ltd., a Chairman by Spinifex Pharmaceuticals Pty Ltd., a Chief Medical Officer & Executive Vice President by Prometheus Laboratories, Inc., an Outside Director by Sosei Group Corp., a Chief Executive Officer & Chief Medical Officer by Amarin Corp.
Plc, a Co-Founder by Topix Pharmaceuticals, Inc., a Senior VP & Head-Worldwide Development by Pfizer Inc., a Professor by Harvard T.H.
Chan School of Public Health, a Chairman by iOx Therapeutics Ltd., a Professor by Kitasato University, a Senior Vice President-Head-Worldwide Development by Pfizer (St. Louis), a Senior Vice President-Clinical R&D by Pfizer Europe International Ltd., a Senior Vice President-Clinical R&D by Pfizer Japan, Inc., and a Professor by University of Glasgow School of Medicine.
He also served on the board at Juvenescence Ltd. and Nxera Pharma UK Ltd. He received his doctorate degree from the University of Glasgow and a doctorate degree from the University of Kent.